March 02, 2015 6:39 PM ET

Healthcare Equipment and Supplies

Company Overview of Amedica Corporation

Company Overview

Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices in the United States. It offers Valeo silicon nitride interbody spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; Valeo stand-alone anterior lumbar intervertebral fusion device; and a line of non-silicon nitride spinal fusion products used by surgeons to promote bone growth and fusion in spinal fusion procedures. The company also develops femoral heads for use in its total hip replacements; and femoral condyle components for use in its total knee replacements. It markets and sells its products to surgeons and hospitals in the United State...

1885 West 2100 South

Salt Lake City, UT 84119

United States

Founded in 1996

74 Employees



Key Executives for Amedica Corporation

Chief Technology Officer
Age: 62
Total Annual Compensation: $228.5K
Compensation as of Fiscal Year 2013.

Amedica Corporation Key Developments

Amedica Announces Receipt Of Nasdaq Notice Of Bid Price Deficiency

Amedica Corporation announced that on February 19, 2015, the Company received a letter from the Nasdaq Listings Qualifications department of the Nasdaq Capital Market ("Nasdaq") notifying the Company that the minimum bid price per share for its common stock was below $1.00 for a period of thirty (30) consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under the symbol "AMDA." Amedica management intends to resolve the situation to allow for continued listing on the Nasdaq Capital Market. The Company has a compliance period of 180 calendar days, or until August 18, 2015, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the 180-day compliance period, the closing bid price per share of the Company's common stock is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance with Rule 5550(a)(2) within this compliance period, it may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff concludes that the Company will not be able to cure the deficiency, or if the Company determines not to submit the required materials or make the required representations, the Company's common stock will be subject to delisting by Nasdaq.

Amedica Corporation Files Submission for 510(K) Clearance of Valeo C Interbody with CsC Osteo-Conductive Scaffolding with U.S. Food and Drug Administration

Amedica Corporation announced that it has filed a submission for 510(k) clearance of the Valeo C Interbody with CsC Osteo-Conductive Scaffolding (Valeo C) with the U.S. Food and Drug Administration (FDA) relating to its composite silicon nitride spinal interbody devices.

Amedica Corporation to Receive U.S. Food and Drug Administration Clearance for Two-Level Cervical Interbody Cage Indications

Amedica Corporation announced that the U.S. Food and Drug Administration (FDA) has expanded the indications of Amedica's silicon nitride interbody fusion products to include multi-level cervical treatment. The FDA's clearance of the expanded indications is based on extensive data from a variety of studies and sources showing the Company's silicon nitride devices used in multi-level procedures are as safe and effective as other devices used in single level procedures. The Valeo™ cervical fusion devices are now indicated for use in skeletally mature patients with degenerative disc disease at one disc level or two contiguous levels. The FDA approval order allows for commercial sales and distribution of these devices for multi-level procedures.

Similar Private Companies By Industry

Company Name Region
Home Care Supply, L.L.C. United States
Circadiance LLC United States
Buckbee-Mears Medical Technologies, LLC United States
Siemens Medical Solutions Diagnostics, Inc. United States
Penrith Corporation United States

Recent Private Companies Transactions

Private Placement
June 30, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Amedica Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at